Viral contamination is an inherent risk during the manufacture of therapeutic products such as antibodies, vaccines, viral vectors, and plasma derivates.
David Cetlin, Biopharma Insights Contributor, Senior Director of R&D at Cygnus Technologies
Advertisement
David Cetlin is Senior Director of R&D at Cygnus Technologies. He can be contacted at david.cetlin@cygnustechnologies.com.
Articles by David Cetlin, Biopharma Insights Contributor, Senior Director of R&D at Cygnus Technologies
Advertisement
Latest Updated Articles
- Predicting Viral Clearance at Your Benchtop
Published: July 27th 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Weekly News Roundup—Week of Oct. 13, 2025
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
4
Futureproofing Viral Safety: Global Perspectives from an Educator, Supplier, and Biosafety Expert
5
